Panelists:
Broadcast Date:
- Time:
Methylation analysis holds significant promise for clinical diagnostics, yet its use has been limited due to challenges posed by legacy technologies that undermine clinical applicability, such as batch effects, PCR biases, and harsh chemical treatments. Native-read sequencing technologies are emerging as a transformative solution, enabling direct and accurate methylation data acquisition—an essential advancement for clinical settings.
In this GEN webinar, experts from the Fred Hutchinson Cancer Center and the Van Andel Institute will discuss all things methylation for early disease detection and precision medicine. They will discuss the current technology ecosystem and key challenges hindering the adoption of methylation data in both solid and blood-based cancers. Additionally, attendees will learn about Wasatch BioLabs’ (WBL) native-read DNA sequencing technologies and how they are bridging the gap between scientific discovery and clinical implementation, providing a unique path forward for the broader clinical adoption of methylation. Key takeaways from the webinar include:
- How WBL’s cfDNA sequencing enables direct cell-of-origin identification, advancing early detection and monitoring of complex diseases like Alzheimer’s.
- How WBL’s proprietary nanopore-based approach eliminates PCR and bisulfite-induced biases, delivering accurate, biologically relevant insights.
- How WBL’s sequencing provides a clear, scalable path for translating biomarker research into clinical application.
A live Q&A session will follow the presentations, offering you a chance to pose questions to our expert panelists.
Produced with support from:
